ESC Premium Access

Significant reduction of Framingham risk score in hypogonadal men receiving long-term testosterone therapy: real-life evidence from a 10-year registry

Congress Presentation

About the speaker

Professor Farid Saad

Bayer AG, Berlin (Germany)
0 follower

6 more presentations in this session

Increased mortality despite successful multifactorial cardiovascular risk reduction in healthy men. 40-year follow-up of the Helsinki businessmen study intervention trial

Speaker: Professor T. Strandberg (Helsinki, FI)


Assessing cardiovascular risk in people with atherosclerotic vascular disease on intensive statin therapy

Speaker: Associate Professor B. Mihaylova (Oxford, GB)


Added predictive value of follow-up blood-pressure measurements after alteration of therapy on cardiovascular risk in patients with hypertension

Speaker: Ms N. Jaspers (Utrecht, NL)


Optimizing outreach strategy to identify individuals at risk for diabetes and/or cardiovascular disease: a study of the Sodertalje municipality in Sweden

Speaker: Doctor B. Shahim (Stockholm, SE)


Associations between very low concentrations of LDL-Cholesterol, hsCRP and health outcomes in the Reasons for Geographical and Racial Differences in Stroke (REGARDS) study

Speaker: Professor M. Banach (Lodz, PL)


Access the full session

Controversies in cardiovascular risk assessment and prevention

Speakers: Professor F. Saad, Professor T. Strandberg, Associate Professor B. Mihaylova, Ms N. Jaspers, Doctor B. Shahim...

About the event


ESC Congress 2018

7 November - 29 August 2018

Sessions Presentations

ESC 365 is supported by

logo Novo Nordisk
logo Bristol Myers Squibb